Tizanidine: Clinical Guidelines and Safety Profile
Dosing Guidelines
Tizanidine should be initiated at low doses (2-4 mg) and titrated slowly over 2-4 weeks, with maximum single doses not exceeding 8 mg and total daily doses not exceeding 24-36 mg, due to limited long-term safety data at higher doses 1.
Specific Dosing Recommendations:
- Initial dose: 2-4 mg, typically at bedtime
- Titration: Increase by 2-4 mg increments every 3-7 days
- Maximum single dose: 8 mg (limited data above this)
- Maximum daily dose: 24-36 mg divided into 3-4 doses
- Peak effect: Occurs within 1-2 hours of administration 1
- Therapeutic variability: Wide interpatient variability requires individualized titration 2, 3
The FDA explicitly warns that clinical experience with single doses above 8 mg or total daily doses above 24 mg is limited, with only approximately 75-80 patients exposed to higher doses for one year or more 1.
Critical Contraindications and Warnings
Absolute Contraindications:
- Concomitant use with CYP1A2 inhibitors (ciprofloxacin, fluvoxamine): This combination produces dangerous drug interactions with 28-37 times increased risk of hypotension 4
- Concurrent use with other α2-adrenergic agonists (e.g., clonidine) 1
- Severe hepatic impairment 1
Black Box-Level Warnings:
Hypotension Risk: Two-thirds of patients taking 8 mg experience a 20% reduction in blood pressure within 1-3 hours, with associated bradycardia, orthostatic hypotension, and rarely syncope 1. The hypotensive effect is dose-related and occurs with doses ≥2 mg 1.
Hepatotoxicity: Approximately 5% of patients develop liver enzyme elevations >3x upper limit of normal, and three fatal cases of liver failure have been reported 1. Monitor aminotransferase levels at baseline, 1,3, and 6 months, then periodically thereafter 1.
Sedation: 48% of patients report sedation (10% severe), with 92% of patients on 16 mg reporting drowsiness 1. This peaks at 1.5 hours post-dose and can persist for 6+ hours.
Major Drug Interactions
High-Risk Interactions:
CYP1A2 Inhibitors (contraindicated):
- Ciprofloxacin: 28-fold increased risk of hypotension 4
- Fluvoxamine: 37-fold increased risk of hypotension 4
- Zafirlukast: 16-fold increased risk of falls 4
Antihypertensive Medications:
- Profound hypotension reported with ACE inhibitors (lisinopril) 5
- Use extreme caution; avoid if possible 1
CNS Depressants:
- Alcohol: Heightened CNS depression and profound hypotension; syncope reported 6
- Benzodiazepines, opioids: Additive sedation and respiratory depression risk
Adverse Effects Profile
Most Common (>10% incidence) 1:
- Dry mouth: 49%
- Somnolence/sedation: 48%
- Asthenia (weakness/fatigue): 41%
- Dizziness: 16%
Serious Adverse Effects:
- Hypotension/syncope: Dose-related, occurs in two-thirds at 8 mg dose 1
- Bradycardia: Associated with hypotensive episodes 1
- Hallucinations/psychosis: 3% incidence, typically within first 6 weeks 1
- Hepatotoxicity: Can be fatal; requires monitoring 1
Special Population Concerns:
Older Adults (≥50 years):
- 28.7% incidence of falls with tizanidine 7
- Increased hospitalizations for encephalopathy, especially with renal impairment 7
- Use with extreme caution; consider alternative agents first 7, 8
Renal Impairment:
- Significantly increased risk of encephalopathy and adverse effects 7
- Dose reduction required
Clinical Context from Guidelines
Tizanidine has demonstrated efficacy for acute low back pain in 8 trials, showing moderate superiority to placebo for short-term pain relief (2-4 days) 9. However, for sciatica, one high-quality trial found no difference between tizanidine and placebo 9. The evidence for chronic low back pain is sparse, with only limited trial data 9.
Skeletal muscle relaxants as a class (including tizanidine) are associated with 2-fold increased risk of CNS adverse events compared to placebo 9. Guidelines recommend them only for short-term use (≤2 weeks) in acute low back pain 10.
Critical Clinical Pitfalls
Do not combine with CYP1A2 inhibitors - this is the most dangerous interaction with up to 37-fold increased hypotension risk 4
Monitor blood pressure closely during titration and for 2-3 hours after each dose increase, especially when moving from supine to standing 1
Obtain baseline and serial liver function tests - hepatotoxicity can be fatal 1
Counsel patients to avoid alcohol completely - syncope and profound hypotension reported 6
Use extreme caution in older adults - nearly 30% fall risk and consider alternative agents first 7, 8
Avoid in patients on antihypertensive therapy - additive hypotensive effects can be life-threatening 5
Warn about sedation - peaks at 1.5 hours and can impair driving and daily activities 1